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Sir: Andrea Stoszkova et al. [1]
conclude, based on a correlation
coefﬁcient of 0.69 comparing subcu-
taneous glucose values (Guardian
RT) and blood glucose values
(Central Laboratory) in 15 patients,
that subcutaneous devices should not
be used in critically ill patients.
However, Holzinger et al. [2] in the
August issue report a good correlation
between subcutaneous and arterial
glucose values, even in critically ill
patients treated with norepinephrine.
We also evaluated the accuracy
and feasibility of a comparable
continuous subcutaneous glucose
monitoring system (CGMS System
Gold, Medtronic Minimed) and found
a correlation coefﬁcient of 0.87 with
the point-of-care blood gas/glucose
analyzer ABL 715 (Radiometer
Medical, Copenhagen, Denmark),
which we validated in ICU patients
previously [3]. We drew 786 arterial
blood samples from 60 consecutive
ICU patients, of whom 37 patients
received vaso-active medication (only
norepinephrine) and 13 patients were
treated with steroids. Blood glucose
ranged from 2.2 to 20.1 mmol/l. In
the Clarke error grid (Fig. 1), 85.1%
of measurements were in zone A
(clinically accurate, leading to correct
and safe treatment decisions), 13.2%
were in zone B (clinically accept-
able), 0.13% were in zone C, and
1.5% were in zone D. Zone D means
failure-to-detect (high or low blood
glucose) errors, resulting in failure to
treat either low or high blood glucose
results appropriately. The readings in
zone D were found in nine patients,
of whom eight were treated with
vasopressors. One could argue that—
with a correlation coefﬁcient of 0.87
and 98.3% of glucose values in the
clinically acceptable zones—rejection
of s.c. glucose determination in the
ICU seems premature.
On the other hand, looking more
precisely at zone D of the Clarke
error grid (Fig. 1), a difference of
nearly 4 mmol/l in the lower glucose
zone (reference 2.8 mmol/l versus s.c.
sensor 6.5 mmol/l) observed in one
patient could have severe conse-
quences in this individual patient, if
this results in an inappropriate rise in
insulin dose. Unlike other diagnostic
procedures, which usually are inter-
preted in conjunction with additional
ﬁndings, a single glucose measure-
ment has direct consequences for
treatment, with potentially detrimen-
tal effects.
In other words, tight glucose
regulation in ICU patients using a
subcutaneous device may lead to
more severe adverse events than the
zone interpretation of the error grid
suggests. The fact that we now have
safe computerized protocols, which
give excellent glucose regulation
with a very low chance of hypogly-
cemic events [4], adds to the feeling
that for glucose regulation in criti-
cally ill patients only the best point-
of-care glucose analyzer and protocol
should be used [5]. In an era where
the beneﬁcial effect of tight glucose
regulation is questioned we cannot
afford the introduction of treatment-
related morbidity.
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Fig. 1 Clarke error-grid analysis
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